23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed. Post navigationPreviousPrevious post:Results of the Combined General Shareholders’ Meeting held on June 29 2018NextNext post:First half of 2018 revenuesRelated PostsUpdate on the restructuring of the AB Science clinical development department in 201819 December 2018Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment22 October 2018Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018First half of 2018 revenues1 October 2018Results of the Combined General Shareholders’ Meeting held on June 29 20183 July 2018Combined General Shareholders’ Meeting held on June 29, 20183 July 2018
Update on the restructuring of the AB Science clinical development department in 201819 December 2018
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis8 October 2018
